Abcam plc Buys Epitomics, Inc. for $170 Million

Published: Mar 07, 2012

March 6, 2012 -- Abcam, a UK maker of protein research tools, will pay $170 million to buy Epitomics, a San Francisco-area company that has developed humanized rabbit monoclonal antibodies for research purposes. Epitomics has an antibody manufacturing facility in Hangzhou that employs more than 200. The company is led by Guo-Liang Yu, PhD, President, CEO and Chairman of the Board. Dr. Yu received an undergraduate degree from Fudan University in Shanghai before immigrating to the US. He did his graduate work at UC Berkeley and Harvard Medical School. More details....

Stock Symbol: (AIM: ABC)

Back to news